Sign in

    Michael F. Mahoney

    President, CEO, and Chairman of the Board at Boston Scientific Corp
    Board
    Since November 2012
    Age
    59 years
    Education
    Holds a B.B.A. in Finance from the University of Iowa and an M.B.A. from Wake Forest University.
    Tenure
    Joined BSX in October 2011 as President, was promoted to President and Chief Executive Officer in November 2012, and appointed Chairman of the Board in May 2016.

    Also at Boston Scientific Corp

    ACB
    Arthur C. Butcher
    Executive Vice President and Group President, MedSurg and Asia Pacific
    DJB
    Daniel J. Brennan
    Executive Vice President and CFO
    ET
    Eric Thépaut
    Executive Vice President and President, EMEA

    About

    At 59 years old , he has built an impressive foundation in business and leadership, underpinned by his studies in finance and administration. Holds a B.B.A. in Finance from the University of Iowa and an M.B.A. from Wake Forest University, which set the stage for a career marked by progressive responsibilities.

    Beginning his career at General Electric Medical Systems, he quickly ascended through the ranks, later serving as President and CEO of Global Healthcare Exchange and holding key leadership roles at Johnson & Johnson. He joined BSX as President in October 2011 and was promoted to President and Chief Executive Officer in November 2012, before being appointed Chairman of the Board in May 2016.

    Beyond his roles at BSX, he has also contributed significantly to the broader healthcare sector through board memberships with prominent companies and participation in non-profit activities. His leadership style, characterized by a focus on operational excellence and strategic vision, has been instrumental in steering the company through dynamic market challenges.

    $BSX Performance Under Michael F. Mahoney

    Past Roles

    OrganizationRoleDate RangeDetails
    Boston Scientific Corporation President, CEO, and Director Nov 2012 - May 2016 Transitioned to also assume Chairman role later
    Boston Scientific Corporation President Oct 2011 - Nov 2012 Joined BSX as President
    Johnson & Johnson Worldwide Chairman, Medical Devices and Diagnostics Division Jan 2011 - Sep 2011 Oversaw 50,000 employees and seven franchises
    Johnson & Johnson Worldwide Group Chairman, DePuy Franchise Apr 2007 - Jan 2011 Managed the orthopedics and neurosciences business
    Global Healthcare Exchange President and CEO Jan 2001 - Mar 2007 Led provider of supply chain solutions connecting hospitals, manufacturers, distributors, and GPOs
    General Electric Medical Systems General Manager, Healthcare IT Business N/A Held various roles over 12 years, culminating in this position

    External Roles

    OrganizationRoleDate RangeDetails
    CVS Health Corporation Board Member N/A Current board member
    Boys & Girls Club of Boston Involved N/A Active involvement
    Boston College CEO Club Chair of the Board of Governors N/A N/A
    American Heart Association CEO Roundtable Member N/A N/A

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$1,400,000Fixed annual cash paymentFixed annual cash amount paid at regular intervals
    401(k) Plan Match$19,800Matching contributions per periodContributions fully vested upon deposit
    Term Life Insurance$4,902Imputed incomeCompany-paid term life insurance imputed as income
    Financial Planning$13,255Service feeFees for financial counseling, investment, retirement, insurance, and tax planning services
    Aircraft Usage$150,000Annual aggregated costCovers personal use of the corporate aircraft up to this amount; excludes fixed operating costs and disallowed tax deductions
    Other Compensation$2,224As specifiedMiscellaneous items not otherwise detailed

    Performance Compensation

    Data from  FY 2023

    rTSR Performance-Based RSUs

    MetricValueCitation
    Performance MetricRelative Total Shareholder Return percentile vs. S&P 500 Health Care Index
    Evaluation Period3 years (Feb 14, 2023 – Dec 31, 2025)
    Threshold30% of target (33,047 RSUs)
    Target100% of target (66,095 RSUs)
    Maximum200% of target (132,190 RSUs)
    Grant DateFebruary 14, 2023
    Grant Date Fair Value$3,124,972
    Grant Date Stock Price$47.28
    Vesting ScheduleVests upon meeting performance and service criteria on Dec 31, 2025

    Organic Net Sales Growth (ONSG) Performance-Based RSUs

    MetricValueCitation
    Performance MetricOrganic Net Sales Growth vs. internal financial plan
    Evaluation Period3 years (2023 – Dec 31, 2025)
    Threshold50% RSU payout at 61.5% of plan
    Target100% RSU payout at 100% of plan
    Maximum200% RSU payout at ≥138.5% of plan
    RSU AllocationsThreshold: 19,828; Target: 66,095; Maximum: 132,190
    Grant DateFebruary 14, 2023
    Grant Date Fair Value$4,222,810
    Grant Date Stock Price$47.28
    Vesting ScheduleVests upon meeting performance and service criteria on Dec 31, 2025

    Stock Options

    MetricValueCitation
    Grant DateFebruary 14, 2023
    Grant Date Fair Value$3,124,984
    Grant Date Stock Price$47.28
    Number of Options171,984
    Exercise Price$47.28
    Vesting ScheduleVests in four equal annual installments starting on the first anniversary

    Service-Based RSUs

    MetricValueCitation
    Grant DateFebruary 14, 2023
    Grant Date Fair Value$3,124,972
    Grant Date Stock Price$47.28
    Number of RSUs66,095
    Vesting ScheduleVests in four equal annual installments starting on the first anniversary

    Overall Long-Term Incentive Award

    MetricValueCitation
    Total Target Award Value$12,500,000 (allocated equally across components)
    Weight Allocation25% each for rTSR RSUs, ONSG RSUs, Stock Options, and Service-Based RSUs
    Current PerformancerTSR and ONSG RSUs tracking at 200% of target as of Dec 31, 2023